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Chronic exposure to periodontopathogenic bacteria such as Porphyromonas gingivalis
and the products of these bacteria that interact with the cells of the tooth surrounding
tissues can ultimately result in periodontitis. This is a disease that is characterized
by inflammation-related alveolar bone degradation by the bone-resorbing cells, the
osteoclasts. Interactions of bacterial products with Toll-like receptors (TLRs), in particular
TLR2 and TLR4, play a significant role in this chronic inflammatory reaction, which
possibly affects osteoclastic activity and osteogenic capacity. Little is known about how
chronic exposure to specific TLR activators affects these two antagonistic activities.
Here, we studied the effect of TLR activation on gingival fibroblasts (GF), cells that are
anatomically close to infiltrating bacterial products in the mouth. These were co-cultured
with naive osteoclast precursor cells (i.e., monocytes), as part of the peripheral blood
mononuclear cells (PBMCs). Activation of GF co-cultures (GF + PBMCs) with TLR2
or TLR4 agonists resulted in a weak reduction of the osteoclastogenic potential of
these cultures, predominantly due to TLR2. Interestingly, chronic exposure, especially
to TLR2 agonist, resulted in increased release of TNF-α at early time points. This effect,
was reversed at later time points, thus suggesting an adaptation to chronic exposure.
Monocyte cultures primed with M-CSF+ RANKL, led to the formation of bone-resorbing
osteoclasts, irrespective of being activated with TLR agonists. Late activation of these
co-cultures with TLR2 and with TLR4 agonists led to a slight decrease in bone resorption.
Activation of GF with TLR2 and TLR4 agonists did not affect the osteogenic capacity
of the GF cells. In conclusion, chronic exposure leads to diverse reactions; inhibitory
with naive osteoclast precursors, not effecting already formed (pre-)osteoclasts. We
suggest that early encounter of naive monocytes with TLR agonists may result in
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differentiation toward the macrophage lineage, desirable for clearing bacterial products.
Once (pre-)osteoclasts are formed, these cells may be relatively insensitive for direct TLR
stimulation. Possibly, TLR activation of periodontal cells indirectly stimulates osteoclasts,
by secreting osteoclastogenesis stimulating inflammatory cytokines.
Keywords: chronic inflammation, toll-like receptors, periodontitis, TNF-α, bone resorption, osteoclasts,
osteoblasts, innate immunity
INTRODUCTION
Periodontitis is a plaque-related inflammatory disease of the
tooth-supporting tissues, leading to alveolar bone resorption
which, eventually, can lead to tooth loss (1, 2). It is initiated
by a disturbed balance between the host immune response and
the bacterial load, modified by several factors such as lifestyle,
genetics, and individual variation in the subgingival microbiome
(3–5). Initially, the inflammatory response plays a protective
role, orchestrated to eliminate the damaging stimulus and restore
symbiosis (6). However, in patients with periodontitis, this
inflammatory reaction is often chronic, leading to the irreversible
alveolar bone resorption, which is mediated by bone-resorbing
cells; the multinucleated osteoclasts (7).
The first line of host defense to micro-organisms or their
products is initiated by the innate immune response. It is
conceivable that gingival fibroblasts (GF), the predominant
cell type of the alveolar bone-lining mucosa (gingiva), interact
constantly with molecules from the oral microflora. These
fibroblasts express receptors that sense the presence of microbes
and substances released by these microbes. These receptors
are referred to as “Pattern recognition receptors” (PRRs) since
they recognize molecular patterns that are commonly present
on many micro-organisms. One of the functions of the innate
immune response is the recognition of pathogen-associated
molecular patterns (PAMPs) by PRRs, including the Toll-like
receptors (TLRs) (8). Up till now, ten TLRs (TLR 1-10) have been
identified in humans which respond to these PAMPs (9, 10). Each
TLR responds to specific PAMPs, however mainly a combination
of them is required to be activated.
All of these TLRs are expressed in periodontal tissues (11, 12).
TLR2 and TLR4 are the most extensively researched receptors
of the TLR family in relation to periodontitis in mice and men
(10, 13–16). This derives from the fact that TLR4 is stimulated by
lipopolysaccharides (LPS) (17), the major glycolipid membrane
component of the Gram-negative bacteria, such as the keystone
periodontopathogenic bacterium Porphyromonas gingivalis (18,
19). TLR2 is involved in the recognition of cell-wall components
of Gram-negative and Gram-positive bacteria. The participation
of these two specific members of the TLR family in the triggering
of the innate immune response in periodontitis patients is already
established (10–12, 20, 21). Accordingly, higher expression of
these receptors has been found in the periodontal tissues of
periodontitis patients, in comparison with healthy controls
(12, 22).
TLR2 and TLR4 are expressed in the periodontal tissues,
and among them on GF (23, 24). GF play an important
role in processes associated with bone remodeling such as
the induction and inhibition of osteoclast formation (25, 26).
Osteoclasts, the cells that are responsible for bone resorption,
are derived from the monocyte lineage and express TLRs which
respond to PAMPs (27). It has been shown that ligature and
injection-induced periodontitis in mice is regulated through the
activation of the TLR4 and TLR2 receptors (28, 29). However,
there is also evidence that shows that the in vitro activation
of human osteoclast precursors with TLR agonists results in
the inhibition of osteoclastogenesis (30). Besides inhibition of
osteoclasts, chronic TLR2 activation plays a significant role in
T cell proliferation, mediated by GF or monocytes, resulting
in the production of proinflammatory cytokines by human
monocytes (24).
GF can also be stimulated into the osteogenic lineage (31).
Little is known about the effect of TLR activation of these cells in
the context of osteogenesis. It has been shown that TLR2 agonist
(Pam3CSK4 or mutant E. coli) slightly enhances osteogenesis
in human primary osteoblasts (32). However, the dose of the
agonists was low (1µg/mL and 1 ng/mL, respectively) and it
was not clearly stated if the agonists were added only once or
with every refreshment of the media. Others found that TLR4
has an inhibitory effect on osteogenesis in murine bone marrow
mesenchymal stem cells (33). Recently, it was shown that in vitro
TLR4 activation in high doses (10µg/mL) inhibits the osteogenic
potential of human periodontal ligament cells (34).
Although periodontitis is a chronic inflammation, and the
expression of TLR2 and TLR4 is aberrant in the GF (24,
35), the effect of the activation of these specific TLRs on
osteoclastogenesis and osteogenesis is only evaluated after short
(<60 h) stimulation (36–40), and scarcely on cells derived from
human periodontal tissues (34, 41–43).
To the best of our knowledge, this is the first study
that evaluated the effect of chronic exposure of specific
TLR2 and TLR4 agonists, molecules that activate TLR2 and
TLR4, both on osteogenesis, in presence of human GF,
and on osteoclastogenesis, in GF stimulated peripheral blood
mononuclear cell (PBMC) cultures. Since TLR stimulators may
also affect precursors of osteoclasts or multinucleated osteoclasts,
we studied these effects on monocytes that were cultured with
macrophage stimulating factor (M-CSF) and receptor activator
of nuclear factor kappa-B ligand (RANKL) for 1 week (pre-
osteoclasts) and for 2 weeks (osteoclasts) followed by 2 vs. 1
week of TLR agonist exposure, to assess the effect on osteoclast
differentiation and activity on bone slices. We hypothesized that
the triggering of these TLRs would result in an induction of
osteoclastogenesis and an inhibition of osteogenesis.
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MATERIALS AND METHODS
Gingival Fibroblasts
GF were obtained from 6 systemically healthy individuals
(age 22–38 years) who underwent extraction of a third molar
(wisdom tooth). No overt signs of gingival inflammation and
periodontitis were present (pockets ≤ 3mm without bleeding).
Sampling from the donors was conducted at VU University
Hospital (Vrije Universiteit, Amsterdam, The Netherlands). All
the individuals signed informed consent and samples were coded
to guarantee the anonymity of the donors as required by Dutch
law. Researchers handling the fibroblasts (G.D. Karlis and T.J. de
Vries) could not retrieve the identity of the donors.
With the use of a scalpel-knife, free gingiva and part of the
interdental gingiva were cut off the tooth. The tissue fragments
were washed twice in culture medium (Dulbecco’s minimal
essential medium (DMEM, Gibco BRL, Paisley, Scotland)
supplemented with 10% fetal calf serum (FCS, HyClone,
Logan, USA), and 1% antibiotics (100 U/mL penicillin, 100
mg/mL streptomycin, and 250 ng/mL amphotericin B [Antibiotic
antimycotic solution, Sigma, St. Louis, MO, USA]) and cultured
in a humified atmosphere of 5% CO2 in air at 37◦C. For the
current study, GF of passages 4–6 were used.
Blood Cell Isolation
Buffy coats (Sanquin, Amsterdam, The Netherlands) of healthy
donors were diluted 1:1 in 1% PBS-citrate (pH 7.4). Thereafter,
25mm of diluted blood was carefully layered on 25mL
Lymphoprep (Axisshield Po CAS, Oslo, Norway) and centrifuged
for 30min at 800 x G without brake. The interphase containing
the PBMCs was collected and washed three times in 1% PBS-
citrate and finally recovered in culture medium.
Monocyte Isolation
CD14+ monocytes retrieved from peripheral blood were used
in experiments where osteoclasts were grown using M-CSF
and RANKL instead of fibroblasts and PBMCs. Here, CD14+
cells were isolated using CD14+ microbeads (Miltenyi, Bergisch
Gladbach, Germany) according to a previously described
method (44).
TLR Agonist Titrations
Optimal cell densities (ratio) of GF and PBMC were previously
established by our group (25). GF (1.5 x 104 per well, n = 3)
were seeded in duplicate and allowed to attach overnight in 48-
well plates. 5 x 105 PBMCs were seeded in duplicate in co-culture
with GF. To assess the optimal concentration of TLR agonists, co-
cultures for osteoclastogenesis cultures as described above or GF
monocultures for osteogenesis (3.0 x 104 cells per well) (31) were
cultured and maintained in a humidified atmosphere of 5% CO2
in ambient air at 37◦C. Cultures were refreshed every 3–4 days.
A titrated concentration of TLR2 ligand (10 ng/mL, PAM2CSK4,
#14E14-MM, Invivogen, San Diego, CA, USA), TLR4 ligand
(10 ng/mL, LPS- Porphyromonas gingivalis, Ultrapure, Version
#14F18-MM, Invivogen), or a combination of both, was added
to the culture media at the start of the experiment (n = 6)
and with every subsequent culture media refreshment (every 3–
4 days). For assessing the effect of TLR2 and TLR4 activation
on TLR activation in general, a TLR2 and TLR4 targeting LPS
from Porphyromonas gingivalis was used (Catalog number #tlrl-
pglps, Invivogen). This LPS activates TLR2 at 10 ng ng/mL and
TLR4 from 100 ng/mL. Both these concentrations were used in
the relative experiments.
Control conditions contained culture media without TLR
agonists but included similar additions of a vehicle (sterile water).
PBMCs were also seeded in high-density cultures at 1 x 106
PBMCs per 96-well plate (n= 4).
CD14+ monocytes were cultured for 3 days in M-CSF
(25 ng/mL), followed by 10 ng/mLM-CSF, and 10 ng/mL RANKL
until 21 days. Pre-osteoclasts at 7 days, or early osteoclasts
at 14 days, received TLR agonists for the remaining 14 or 7
days respectively.
TRAcP Staining
After 21 days, cells were fixed in 4% PBS-buffered formaldehyde
for 10min and washed with PBS. Cells were stained
with a TRAcP staining (Sigma-Aldrich) according to the
manufacturer’s protocol. Nuclei were counterstained with 4′,6-
diamidino-2-phenylindole (DAPI) for 5min. A combination
of light and fluorescence microscopy (Leica DFC320; Leica
Microsystems, Wetzlar, Germany) was used to count the TRAcP
+ multinucleated cells (MNCs) and cells were considered to be
osteoclasts when TRAcP positive with at least three nuclei. Five
standardized areas per well were analyzed at a magnification of
20 x to count the number for the number of MNCs containing at
least three nuclei and are expressed as MNCs/ well.
Bone Resorption
Bone resorption was analyzed in cultures on bone after a
culture period of 3 weeks. After this period, the cells present
on the bovine cortical bone slices were removed with 0.25M
NH4OH. The slices were washed in distilled water, incubated in
a saturated alum solution, washed in distilled water, and stained
with Coomassie Brilliant blue. The surface areas of individual
resorption pits were measured using Image-Pro Plus software
(Media Cybernetics, Silver Spring, MD).
Osteogenesis
Osteogenesis assays were performed as previously described
(14, 31). Briefly, GF were seeded in 48-wells plates (3 x 104
cells/well). Culture medium (0.4mL per well) was replaced
twice per week. The culture medium contained 50µg/mL
ascorbic acid (Sigma) and 10 nM β-Glycerophosphate (Sigma),
which are conductive to mineralization (further referred to as
mineralizationmedium).Water as solvent control, TLR2 agonist,
TLR4 agonist, or the combination of these agonists was added for
21 days. Cells were harvested for quantitative PCR analysis by
adding RNA lysis buffer (Qiagen, Hilden Germany) containing
1% β-mercaptoethanol and were stored at −80◦C until RNA
extraction. Cells for alkaline phosphatase activity and DNA
measurements were lysed in Milli-Q water and stored at −20◦C.
The cells for the mineralization assay were fixed with 4% PBS
buffered formaldehyde for 10min and were stored with PBS
at 4◦C.
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In order to evaluate the osteogenic capabilities of the TLR
agonists in vitro, we measured the calcium deposition (µg/mL),
in the 4 different conditions (with TLR2, TLR4, TLR2 + TLR4,
and without, respectively) and at 4 different time-points (t = 0, 7,
14, 21 days).
Alkaline Phosphatase
Alkaline phosphatase activity (ALP) was measured in lysates
from cells that were cultured with mineralization medium.
Cells were harvested at days 0 and 14 of culturing. Cells were
washed with PBS and lysed with 200 µL Milli-Q water and
were frozen in−20◦C for storage. After three freeze-thaw cycles,
samples were collected by scraping. ALP wasmeasured according
to the method described by Lowry (45), using 4-nitrophenyl
phosphate disodium salt (Merck, Darmstadt, Germany) at pH
10.3, as a substrate for ALP. Absorbance was measured at 405 nm
with a Synergy HT spectrophotometer (BioTek Instruments
Inc., Winooski, VT, USA). DNA was measured in the same
lysate using CyQuant Cell Proliferation Assay Kit (Molecular
Probes, Leiden, The Netherlands). Fluorescence was measured
at 485 nm excitation and 528 nm emission with a Synergy HT
spectrophotometric microplate reader. Alkaline phosphatase was
expressed as µmol/ng DNA.
Alizarin Red Staining
Mineral deposition, in triplicate wells per donor, was analyzed
after 21 days of culturing. The cells were fixed for 10min in
4% formaldehyde and rinsed with Milli-Q water before adding
300 µL of 2% Alizarin Red solution at pH 4.3 (Sigma-Aldrich,
St. Louis, MO, USA). After incubation of 15min at room
temperature, the cells were washed with Milli-Q water and air-
dried. Red nodules were a sign of mineral deposition.
Calcium Quantification
Samples for calcium deposition assay were collected on days 0,
14, 21. First, 1mL of 0.5M acetic acid was added. Secondly,
calciumwas extracted by shaking the samples overnight. Calcium
content was measured in the extraction solution using the ortho-
cresolphthalein complexone (OCPC) method (46). Absorbance
was measured at 570 nm in a microplate reader (BioTek
Synergy HT).
Scanning Electron Microscopy
Mineralization assays were performed on cells that were grown
on glass insert slides, in the presence or absence of TLR
agonists and mineralization medium. At 21 days, cells were
washed in cacodylate buffer, fixed in MacDowells fixative, and
dehydrated in steps of increasing percentage of ethanol. Gold-
sputtered preparations were analyzed with a Zeiss Sigma 300
FESEM (Carl ZeissMicroscopy GmbH, Jena, Germany) scanning
electron microscope.
ELISA
Conditioned medium was taken from mono- and co-cultures (n
= 6) at 3, 7, and 21 days. Enzyme-linked immunosorbent assays
(ELISA, R&D Systems, Minneapolis, MN, USA) were used for
the detection of human tumor necrosis factor alpha (TNF-α)
following the manufacturer’s instructions.
Real-Time Quantitative PCR
After 7 and 21 days of culturing, RNA was extracted from
samples using a commercial spin-column kit (RNeasy Mini kit,
Qiagen, Düsseldorf, Germany) according to the manufacturer’s
protocol. RNA concentration was measured with Synergy
HT spectrophotometer (BioTek Instruments Inc., Winooski,
VT, USA). One hundred nanograms RNA was used in the
reverse transcriptase reaction which was performed according
to the manufacturer’s instructions of the MBI Fermentas cDNA
synthesis kit (Vilnius, Lithuania), using both the Oligo(dT)18
and the D(N)6 primers. The Primer Express software, version 2.0
(Applied Biosystems, Foster City, CA, USA) (Table 1) was used
to design the Real-time PCR primers.
Real-time PCR was performed on the ABI PRISM 7000
(Applied Biosystems). The reactions were performed with 5 ng
cDNA in a total volume of 25mL containing SYBR Green PCR
Master Mix, consisting of SYBR Green I Dye, AmpliTaq Gold
DNA polymerase, dNTPs with dUTP instead of dTTP, passive
reference and buffer (Applied Biosystems) and 300 nM of each
primer. After an initial activation step of the AmpliTaq Gold
DNA polymerase for 10min at 94◦C, 40 cycles were run of a two-
step PCR consisting of a denaturation step at 94◦C for 30 s and
annealing and extension step at 60◦C for 1min. Subsequently,
the PCR products were subjected to melting curve analysis to
test if any unspecific PCR products were generated. The PCR
reactions of the different amplicons had equal efficiencies. β2-
microglobulin was used as the housekeeping gene. Expression
of this gene was not affected by the experimental conditions.
Samples were normalized for the expression of β2-microglobulin
by calculating the 1Ct, (Ctgene of interest -Ct,β2−microglubulin) and
expression of the different genes is expressed as the mean relative
fold expression 2−(1Ct).
Statistics
GraphPad Prism software (version 8.3.0, La Jolla, CA, USA)
was used to analyze the data sets. Means and standard
deviations (SD) were calculated and used for the presentation
of the data in figures. All the data were analyzed with one-
way ANOVA followed by Tukey’s multiple comparison test.
Tests were performed over the 4 (osteoclastogenesis) or 5
(osteogenesis) conditions per time point and per condition over
time. Differences were considered significant at p < 0.05.
RESULTS
Chronic Exposure to TLR Agonists
Decreases the Osteoclastogenic Capacity
of GF-PBMC Co-cultures
In order to identify the most suitable concentration of TLR
agonists for the experiment, various concentrations of TLR2
and TLR4 were tested (0.1, 1, 10, and 100 ng/mL). For
osteoclastogenesis experiments, GF and PBMCswere co-cultured
for 21 days with or without TLR agonists. In order to identify
osteoclasts, TRAcP+ cells with more than 3 nuclei were counted
and categorized into three different groups (3–5, 6–10, and ≥11
nuclei) (47). Because the vast majority of the multinucleated
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cells had 3–5 nuclei, all three categories were merged into one
category. The addition of TLR2 and TLR4 agonists appeared
to be associated with the formation of fewer multinucleated
cells (Figures 1A,B). This effect was statistically significant for
all concentrations, except for the 0.1 ng/mL TLR2 condition
(Figure 1A).
TLR2 Agonist Decreases the Number of
Multinucleated Cells in GF-PBMC
Co-cultures
Based on the results of the titration experiment (Figure 1),
a concentration of 10 ng/mL of TLR agonists was chosen for
further experiments. To analyze whether activation of both TLR2
and TLR4 would lead to increased sensitivity, a condition of
10 ng/mL of both TLR2 and TLR4 agonist was included in all
further experiments. GF were co-cultured with PBMCs for 21
days. The cells were stained for TRAcP activity and cells with
3 or more nuclei were counted as multinucleated cells, in 5
standardized fields per well. The presence of TLR2 and TLR2 +
4 agonists was significantly associated with fewer multinucleated
cells, in comparison with the control (Figure 2A), suggesting
that TLR2 agonist decreased the number of MNCs in these co-
cultures. Apart from GF-PBMC co-cultures, there is another way
to culture multinucleated cells in the absence of cytokines. When
PBMCs are plated at a high density, multinucleated cells will form
(48). Here, T-cells seem important for providing the signals for
the formation of multinucleated cells (49). Also, when applying
this method, less multinucleated cells formed when TLR2 agonist
was added (Figure 2B). Multinucleated cells were counted on
bovine bone slices. The presence of these cells on the bone
TABLE 1 | Primer sequences used for RT-qPCR experiments.
Gene Primer sequence Ensembl gene ID
TRAcP Forward 5′ CACAATCTGCAGTACCTGCAAGGAT 3′ ENSG00000102575
Reverse 5′ CCCATAGTGGAAGCGCAGATA 3′
NFATc1 Forward 5′ CATGCGAGCCATCATCGA 3′ ENSG00000206439
Reverse 5′ TGGGATGTGAACTCGGAAGAC 3′
TNF-α Forward 5′ CCCAGGGACCTCTCTCTAATCA 3′ ENSG00000111956
Reverse 5′ GCTTGAGGGTTTGCTACAACATG 3′
RUNX2 Forward 5′ CCAGAAGGCACAGACAGAAGCT 3′ ENSG00000124813
Reverse 5′ AGGAATGCGCCCTAAATCACT 3′
ALP Forward 5′ GCTTCAAACCGAGATACAAGCA 3′ ENSG00000162551
Reverse 5′ GCTCGAAGAGACCCAATAGGTAGT 3′
Osteonectin Forward 5′ GCCCAGCGGTGCAGAGT 3′ ENSG00000196104
Reverse 5′ GGCTCCCAGCCATTGATACA 3′
TLR2 Forward 5′ GGCTTCTCTGTCTTGTGACCG 3′ ENSG00000137462
Reverse 5′ GAGCCCTGAGGGAATGGAG 3′
TLR4 Forward 5′ CTGCAATGGATCAAGGAACCAG 3′ ENSG00000136869
Reverse 5′ CCATTCGTTCAACTTCCACCA 3′
β2-microglobulin Forward 5′ CGGGCATTCCTGAAGCTGA 3′ ENSG00000106927
Reverse 3′ GGATGGATGAAACCCAGACACATAG 3′
FIGURE 1 | Effect of Toll-like receptor (TLR) agonist concentrations on the osteoclastogenic and the osteogenic capacity of gingival fibroblasts (GF). (A) The number
of multinucleated cells formed in the presence of TLR2 agonist (0.1–100 ng/ml). (B) The number of multinucleated cells formed in the presence of TLR4 agonist
(0.1–100 ng/mL). Titration experiments were performed using three different GF donors in duplicates, average results ±SD are shown. Significant results for (A) and
(B) are shown (black bars). *p < 0.05, **p < 0.01.
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FIGURE 2 | TLR2 agonist decreases the number of multinucleated cells in GF-PBMC co-cultures and PBMC high-density cultures. The number of multinucleated
cells is presented in (A–D). The concertation of the agonists was 10 ng/mL. Osteoclast formation is particularly decreased in the presence of TLR2 (light gray bars,
A,B) and TLR2+4 agonists (black bars, A). (C) Multinucleated cells were counted on bone slices but they were in very low numbers. (D) In high density cultures,
multinucleated cells were a more common finding but without any difference between the conditions. Cells were stained for tartrate-resistant acid phosphatase
(TRAcP, purple) and counterstained with DAPI (blue), in order to detect the multinucleated cells (depicted with yellow arrows); on plastic (E) and on bone (F). All
micrographs are representatives for three independent experiments with six different GF sources. Scale bar represents 100µm. (G) TRAcP enzyme activity was
measured by three different conditions, each with separate 0 days and a 21 days control samples. TRAcP enzyme activity is significantly decreased at day 21 at the
TLR2+4 condition in comparison with the control. (H,I) Real-time quantitative PCR was performed for the genes of TRAcP and NFATc1). n = 6 GF cultures per
condition in duplicates, average results ±SD are shown. For the HD cultures n = 4. Significant results for (A–D) and (G–I) are shown (black bars). *p < 0.05,
**p < 0.01, ***p < 0.005, ****p < 0.001. aHigh density culture.
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was rare (Figure 2C). Multinucleated cells on bone found to be
more often present in high-density cultures compared to normal
density co-cultures on bone. No significant differences were
found (Figure 2D) on bone slices, suggesting that the surfacemay
modulate TLR agonist’s activity. Representative micrographs of
TRAcP+ cells on plastic and on bone are shown in Figures 2E,F,
respectively. The TRAcP enzyme was also quantified at baseline
(day 0) and day 21 (Figure 2G). TRAcP enzyme was statistically
decreased at day 21 under the effect of TLR2+4 in comparison
with the control. The expression of TRAcP mRNA was measured
also with Real-Time qualitative PCR (Figure 2H). A trend
of less expression in the conditions of TLR2 and TLR4 in
comparison with the control was found without being statistically
significant. The only difference was found between TLR2 and
TLR2+4 at day 7, with the TLR2+4 being elevated compared
to TLR2 (Figure 2H). The gene expression of NFATc1, a crucial
transcription factor for osteoclast formation (50) was measured
(Figure 2I). Expression of NFATc1 was significantly lower for
TLR2 in comparison with the control, at day 7. At day 21, the
expression of the gene was significantly lower in the conditions
of control and TLR2+ 4 in comparison with day 7.
Secretion of TNF-α: Early TLR2 Agonist
Responses and Nullification Over Time
We previously described, that TLR activation results in the
production of inflammatory cytokines (24). We next measured
TNF-α in the supernatant of GF-PBMC co-cultures (Figure 3).
Since little is known about the production of TNF-α in
chronically TLR agonist exposed cultures, we measured TNF-α
at 3 different time points; at 3, 7, and 21 days. At day 3, the
levels of TNF-α were significantly elevated in the groups that
contained TLR2 agonists (TLR2 and TLR2+4) in comparison
with the control (Figure 3). At day 7, these results were reversed,
where the levels of TNF-α of the control and TLR4 conditions
were significantly higher than when TLR2 agonist was added. On
day 21, secretion of TNF-α was significantly lower when TLR2
agonist was added compared to TLR2+4 agonists.
Effect of TLR Agonists on the Number of
Multinucleated Cells and Bone Resorption
in Monocyte Cultures Stimulated With
M-CSF and RANKL
The above described osteoclastogenesis inhibitory effects by
TLR2 and TLR4 agonists that were performed on cultures with
naive monocytes, present in PBMCs that were stimulated with
TLR agonists right after isolation. Although the GF-PBMC co-
culture and the high-density PBMC cultures are good models
to investigate the formation of multinucleated cells under the
influence of GF or T-cells respectively, resorption by these
multinucleated cells has never been observed (48, 51). In fact,
the addition of M-CSF and RANKL is essential to achieve
bone resorption (25). To further investigate TLR activation
on osteoclast precursors of various stages of differentiation,
TLR2 and TLR4 agonists were added to monocyte cultures
that were stimulated with M-CSF and RANKL on day 7
(early stage osteoclast differentiation), day 14 (late stage, just
FIGURE 3 | TLR2 agonist has an evident effect on TNF-α; increasing in early
timepoints, reversed later. TNF-α is significantly elevated at day 3 in all
conditions containing TLR2 agonist (light gray and black); at day 7, these
conditions are significantly decreased in comparison with the control. At day
21, the are no differences anymore between TLR conditions and control. n = 6
GF cultures per condition in duplicates, average results ±SD are shown.
Significant results are shown (black bars). *p < 0.05, ****p < 0.001, $p < 0.01
for the same condition between day 3 and day 7, day 3 and day 21 as well as
day 7 and day 21, ∧p < 0.001 for the same condition between day 3 and day
7, as well as day 3 and day 21, !p < 0.001 for the same condition between
day 3 and day 7.
before resorption takes place), or not at all (control condition)
(Figure 4A). Cultures were terminated after 21 days. The cells
were stained for TRAcP activity and DAPI and cells with 3
or more nuclei were counted (depicted with yellow arrows in
Figure 4D). The addition of TLRs on day 7 and day 14 was
not associated with a change in the number of multinucleated
cells (Figures 4B,D which depicts condition II). For the cultures
that were cultured on bovine bone slices (Figure 4E), bone
resorption was quantified (Figure 4C). Bone slices were stained
with Coomassie Brilliant blue and resorption pits were identified
and their surface was measured using Image-Pro Plus software
(Media Cybernetics, Silver Spring, MD). Bone resorption was
hardly affected when TLR agonists were added, both when added
at 7 or at 14 days. The only conditions that differed statistically
with the control were TLR2 and TLR4, both when added
on day 14. These experiments show that chronic exposure to
TLR2 or TLR4 agonists did not affect osteoclast formation from
osteoclast precursors or already formed osteoclasts. Furthermore,
no increase in bone resorption was observed, rather slightly
decreased bone resorption compared to conditions without TLR
activation (Figure 4C).
GFs Express TLR2 and TLR4 but at a
Lower Level Compared to Osteoclasts
In order to confirm the expression of TLR2 and TLR4 by
the cells of interest, RT-qPCR was performed (Figure 5). Co-
cultures and CD14+ cultures stimulated with M-CSF and
RANKL were cultured with a Pg-LPS that targets both TLR2 and
TLR4, depending on the concentration. TLR2 is activated from
10 ng/mL, TLR4 from 100 ng/mL. Both these concentrations in
M-CSF and RANKL stimulated monocyte cultures were used.
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FIGURE 4 | Effect of TLR agonists on the formation of multinucleated cells and on bone resorption in CD14+ monocyte cultures stimulated with M-CSF and RANKL.
(A) Flow chart of the conducted experiment. Day 0–3: monocytes were cultured with M-CSF. Day 3–7: M-CSF + RANKL were added to the monocyte cultures. Day
(Continued)
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FIGURE 4 | 7: Under the effect of M-CSF + RANL, monocytes have formed pre-osteoclasts. Control condition: no TLR agonists were added to this culture; Condition
I.: TLR agonists were added to pre-osteoclasts from day 7 to 21 (chronic exposure on pre-osteoclasts); Condition II.: TLR agonists were added to osteoclasts from
day 14 to 21 (chronic exposure on osteoclasts before resorption). Cultures were terminated after 21 days. (B) Osteoclasts were counted. Condition I and condition II
are shown in the x-axes (7–21 and 14–21 days, respectively). Osteoclast formation did not differ between the conditions. (C) Bone resorption was measured. Addition
of TLR agonists did not affect bone resorption when added at day 7 and had a slightly inhibitory effect on bone resorption when added from day 14–21 for both TLR2
and TLR4 agonist. (D) Shows light microscopy micrographs of the TRAcP stained cells, and the DAPI counterstained nuclei. Traces of bone resorption were regularly
noticeable, for instance in the condition with TLR2 agonist. (E) Resorption pits were quantified after staining with Coomassie brilliant blue. Examples are shown from
TLR agonist exposures from 14 to 21 days. Bars in micrographs represent 100µm (D) and 200µm (E). Data from 1 out of 2 experiments are shown, similar results
were obtained in both experiments. n = 4 per condition, in quadruplicates; average results ±SD are shown. Significant results for (B,C) are shown (black bars).
*p < 0.05.
The expression of TLR2 and TLR4 in mono-cultures of GFs (t
= 0) and in co-cutures of GF-PBMCs was measured at 3 different
time points (t = 7, 14, and 21 days), after triggering with Pg-LPS
that targets both TLRs at concertations of 10 ng/mL or 20 ng/mL
and 100 ng/mL (Figure 5A). No differences were found between
the conditions, indicating that TLR2 and TLR4 are expressed
constantly over time, independent of the LPS concentration. The
only significant difference was a reduction of the expression of
TLR4 from day 7 to day 14, at the concentration of 10 ng/mL.
The expression of TLR2 and TLR4 was measured also in CD14+
cultures that were stimulated with MCS-F and RANKL, at 21
days, the timepoint when all cells are in the osteoclast lineage,
either as TRAcP mononucleated or as multinucleated cells
(Figures 5C,D). Osteoclasts expressed both TLR2 and TLR4, at
a much higher level than GF or GF-PBMC co-cultures.
TLR2 and TRL4 Agonists Do Not Affect the
Osteogenic Capacity of the Gingival
Fibroblasts
To establish the effect of TLR2 and TLR4 agonists on
osteogenesis, different osteogenic assays were conducted.
Alkaline phosphatase and DNA content were measured at
baseline (day 0) and day 14, with and without osteogenic
medium (Figure 6A). There were no significant differences
between the control and the other conditions on day 14.
However, the addition of especially TLR4 agonists seemed
to reduce the number of cells on day 14 (Figure 6B). The
calculated ALP/DNA, or alkaline phosphatase corrected per
number of cells, was not significantly different, with a lot
of variation between the conditions (Figure 6C). Deposited
calcium was measured at three different time points (t = 0, 14,
and 21 days, Figure 6D). On day 14 and 21, calcium was only
measured in conditions cultured in osteogenic medium and
the concentration of calcium increased between day 14 and
21. However, the addition of TLR agonists did not influence
calcium deposition (Figure 6D). Alizarin red staining confirmed
these findings; no effect of TLR activation was observed
(Figure 6E). Mineralization was confirmed with scanning
electron microscopy (SEM, Figure 6F). Mineralization was
present on top of cells (Figure 6Fi), as nodular structures,
sometimes containing fibrillar structures, reminiscent of bone
matrix proteins such as collagen I (Figure 6Fii).
Unlike the osteoclastogenesis experiment with co-cultures,
TNF-α protein was undetectable in the supernatants of
osteogenic cultures stimulated with TLR agonists (Figure 6G).
However, at the mRNA level, low expression of TNF-α was
detected, only significantly higher expression was found when
TLR2 and TL4 agonists were added together at day 14
(Figure 6G). Early osteogenic marker RUNX2 was upregulated
compared to t = 0 only in cultures with both TLR2 and TLR4,
but no differences were found between conditions per time point,
or between 7 and 14 days (Figure 6H). Intermediate marker
ALP was upregulated at 7 days, especially in conditions where
TLR4 agonist was added. As expected for ALP, the expression
was lower at 14 days. No significant differences were observed
between the conditions at 14 days (Figure 6I). Remarkably, late
osteogenic marker osteonectin was significantly higher expressed
at 7 days compared to 14 days (Figure 6J). Between conditions
per time point, no significant differences were observed. Overall,
influences of TLR agonists were limited in all gene expression
analyses (Figures 6G–J).
DISCUSSION
Chronic diseases associated with bacterial pressure, such as
periodontitis, are likely to experience phases of chronic exposure
to bacterial products such as TLR activators. The effects of
chronic exposure of cell cultures to TLR activators have been
grossly neglected. In the present article, we describe the effects
on osteoclast formation and activity on the one hand and on
the osteogenic aspects on the other hand in cultures of GF
that were chronically exposed to agonists of TLR2, TLR4, and
their combination. TLR2 and TLR4 are the predominant TLRs
activated in periodontitis (12, 22, 52).
A key finding of our study is that osteoclast formation is
inhibited by TLR agonists when freshly isolated PBMCs are used.
This was observed both in the co-culture’s studies using GF and
in the so-called high-density cultures. One could interpret these
results in terms of the necessities of the inflamed periodontium,
where relatively naive migrating monocytes may be triggered to
differentiate into macrophages to nullify the effect of the bacterial
products. The TNF-α ELISA results are in support of such a view:
co-cultures produced high levels at early time points, especially
in the presence of TLR2 agonists.
Intriguingly and relevant for our understanding of the
immune reactions that take place during an infection is our
finding that continuous exposure to TLR activators does not
alter osteoclast differentiation when first primed with M-CSF
and RANKL, both when added at the pre-osteoclast stage of 7
days and when added at the osteoclast stage of 14 days. This
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FIGURE 5 | GFs and monocytes express TLR2 and TLR4. (A) Expression of TLR2 and (B) TLR4 in GFs cultures (t = 0) and co-cultures of GFs and PBMCs (t = 7, 14,
and 21). (C) Expression of TLR2 and (D) TLR4 in cultures of CD14+ cells, cultured with M-CSF and RANKL. LPS-PG (Invivogen, San Diego, CA, USA) was used as
TLR2 and TLR4 agonist in concentrations of 10 ng/mL or 20 ng/mL and 100 ng/mL. n = 6 for the co-cultures and n = 4 for the CD14+ cells’ culture; average results
±SD are shown. Significant results are shown (black bars). ***p < 0.001.
could indicate that the TLR-related induction of bone resorption
in vivo (28, 29, 38), is due to the activation of the inflammatory
milieu rather than directly through the osteoclast. In other words,
the TLR reaction could elicit local stimulators of osteoclast
differentiation such as IL-1β (53, 54) or TNF-α (55). Though
not assessed, our results make it unlikely that osteoclasts or
osteoclast precursors will express autocrine levels if osteoclast
activate themselves after long-term exposure to TLR activators.
To the best of our knowledge, this is the first study that
investigates the effect of TLR agonists in osteoclastogenesis and
osteogenesis in a model of chronic exposure. Additionally, it
is the only study that evaluated both osteoclastogenesis and
osteogenesis on human periodontal cells, and more specifically
GF. There are a few studies (34, 42, 43) that have studied the
osteogenic potential of human periodontal ligament cells (hPDL)
exposed to TLR agonists, sometimes with conflicting results. In
two independent studies (42, 43), hPDL cells were infected with
E. coli LPS (TLR4 agonist) and it was found that the osteogenic
capacity of the cells was reduced significantly. In another study
(34), the effect of TLR ligands was investigated on hPDL cells.
High doses of TLR1, TLR3, and TLR6 ligands inhibited the
osteogenic potential of these cells. On the contrary, Albiero
et al. (41) infected hPDL cells with Porphyromonas gingivalis LPS
(TLR2 agonist) and found no additional effect on the osteogenic
differentiation potential of these cells. However, in this study was
not clearly stated if the TLR agonists were added in the culture
media only once or also in every refreshment. The osteogenic
gene analyses of the above studies were limited to 2 weeks of
cultures. For Alizarin red staining, the cells were cultured for 21–
28 days. In these experiments, we unequivocally showed no effect
of TLR2, TLR4, or the combination of the two when taking into
account parameters like alkaline phosphatase, calcium deposition
or Alizarin red staining. TLR4 could have a slight influence on
the level of ALP at mRNA levels, or, in combination with TLR2
on the mRNA expression of TNF-α. Our results are in line with
the findings of Albiero et al. (41), as we also found that the
addition of TLR2, TLR4, and the combination of those agonists
do not affect the osteogenic potential of the GF. Of special
interest: the qPCR data from the osteogenesis were only partly
in line with what is commonly seen in osteogenic differentiation.
RUNX-2 was highest at an early timepoint, demonstrating its
early osteogenic differentiation character. ALP expression was
surprisingly highest at day 7 and significantly so in all conditions
compared to day 0. Under normal circumstances, ALP protein
expression peaks at 14 days (14), apparently the enhanced protein
expression is prepared 1 week earlier. Osteonectin expression
is believed to be a late marker of osteogenic differentiation,
not seen in our results where expression lowered at day 14.
When comparing gene expression of all genes, it is remarkable
that addition of mineralization medium seemed not to influence
gene expression of osteogenic genes. Apparently, the inevitable
increased cell density seen in the wells might in part control
gene expression. TLR2 and TLR4 agonists did not change gene
expression, but interestingly the combination of the two altered
TNF-α expression, the only assay where a synergistic effect
was seen in our study. The apparent different-from-expected
expression patterns of ALP and osteonectin, could be due to
the fact that gingival fibroblasts are less suited for osteogenic
differentiation compared to periodontal ligament fibroblasts (56).
Scanning electron microscopy confirmed that mineral nodules
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FIGURE 6 | TLR agonists do not affect the osteogenic capacity of gingival fibroblasts. (A) Alkaline phosphatase (ALP), (B) DNA, (C) alkaline phosphatase corrected
per number of cells (ALP/DNA), and (D) calcium deposition were quantified. (B) Compared to control cultures, TLR4 agonist (alone or with TLR2) affected the
proliferation of cells. Overall, no significant differences were observed between the control conditions and the TLR agonists for (A) ALP, (C) Calcium deposition, and
(E) Alizarin red staining. Alizarin red staining was done using control conditions without (C–) or with (C+) mineralization medium. The staining showed heterogeneity
between the 6 donors. (Fi) Shows the osteogenic matrix under scan electron microscopy and (Fii)presents structures that resemble mineral nodules. (G–J) Present
the results of the quantitative PCR. (G) TNF-α is positively mediated by the combination of TLR2+4 at early and late time points (day 7 and 14). (H) RUNX2 is only
increased at day 7 by the combination of TLR2+4, in comparison with the baseline (day 0). (I) Expression of the ALP gene is elevated in all conditions at day 7 in
comparison with the baseline (day 0). TLR4 is also elevated compared to the negative and positive controls at day 7 and compared to the TLR4 at day 14. TLR2+4
reduced significantly from day to day 14. (J) Osteonectin gene expression reduced significantly from day 7 to day 14 for the control, TLR4 and TLR2+4. n = 6 per
condition in duplicates, average results ±SD are shown. Significant results for (A–D) and (G–H) are shown (black bars). *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001 in comparison to all the other conditions, #p < 0.0001 in comparison to the c (+), TLR2, TLR4, and TLR2+4 at day 21, %p < 0.001 in comparison to
TLR2+4 at day 14.
were formed by the GF. A previous study (57) showed that it is
possible to isolate and culture mesenchymal cells from human
GF, which showed osteogenic differentiation capacity.
With respect to osteoclastogenesis, our results reject the
hypothesis of this paper. Based on in vivo studies in mice (38, 39,
58–60) which Pg-LPS have shown that TLR activation induces
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osteoclastogenesis and bone resorption, we hypothesized that
the activation of the TLR ligands would lead to induction of
osteoclasts formation and bone resorption. Our results present
a mild inhibition of the formation of osteoclasts in the co-
cultures and slight reduction of bone resorption. Ji et al. (30)
studied osteoclastogenesis in monocytes cultures, primed with
M-CSF, activated with TLRs or IFN-γ, and also in an in vivo
murine model. They concluded that activation with TLR2
and TLR4 ligands results in inhibition of osteoclastogenesis
via inhibition of RANK and CSF1R expression. In another
study (61), they studied the formation of osteoclasts in murine
bone marrow cells, activated with TLR2 and TLR4 ligands.
These cells were primed with M-CSF + RANKL or only with
M-CSF and the RANKL was added concomitantly with the
TLR ligands (TLR2 and TRL4). They found that TLR ligands
inhibited RANKL-mediated osteoclastogenesis when the ligand
and RANKL were simultaneously added to the cultures. On the
contrary, when the cells were primed with M-CSF and RANKL
before the activation with the ligands, osteoclastogenesis was not
arrested. In the recent review of Souza and Lerner (62), it is
also supported that activation of TLR agonists in different stages
affects differently the maturation of the osteoclasts. Concomitant
addition of TLR agonists and RANKL at the stage of osteoclast
progenitor cell leads to impaired osteoclastogenesis. On the
contrary, osteoclast progenitor cells primed with RANKL and
then activated with TLR agonists, in the absence of RANKL,
differentiated into mature osteoclasts. Our results show an
inhibition of the naive osteoclast precursor cells, whereas the
already formed (pre-)osteoclasts were not affected, which is in
line with these studies. As they state in the paper of Ji et al. (30),
FIGURE 7 | TLR activation affects osteoclastogenesis differently, depending on the differentiation stage of the blood cells, but does not affect osteogenesis.
(A) Activation of human peripheral blood mononuclear cells (PBMCs) with TLR2 and TLR2+4 agonists, in presence of GF, decreases the formation of osteoclasts.
(B) Priming of monocytes with M-CSF + RANKL leads to formation of pre-osteoclast. Triggering of these cells with TLRs in an early stage (from day 7 to 21),
concomitant with M-CSF and RANKL, induces formation of bone resorbing osteoclasts. When the TLRs are added on a later stage (from day 14 to 21), the bone
resorption capacity of the osteoclasts is reduced. (C) Triggering of GF with TLRs, in presence of mineralization medium, precipitates osteogenesis.
Frontiers in Immunology | www.frontiersin.org 12 July 2020 | Volume 11 | Article 1693
Karlis et al. Chronic TLR Activation and Periodontitis
the inhibition of the osteoclastogenesis can be explained as a
homeostatic reaction against the inflammatory effects. Another
possible explanation of our findings, as stated earlier in the
discussion, could be that the activation of the monocytes with
the TLR ligands (and more specifically the TLR2) leads to the
formation of more macrophages instead of osteoclasts. This
scenario could also be related to highly increased concentrations
of TNF-α that we found on day 3 in the conditions of TLR2
and TLR2+4.
Another interesting implementation of our study was the 21
days duration of our experiments. The previously mentioned
osteoblasts cultures (34, 41–43) were executed as well in a 21
days’ timeframe, as this time is needed for the formation of
osteoblasts. Regarding the osteoclastogenesis, this is the first
experiment that evaluated the effect of the TLRs in a timeframe
of 21 days. Most of the studies that were performed studied the
formation of osteoclasts in a timeframe of 2–5 days, typical for
mouse osteoclasts (36–40), and in the studies of Kassem et al.
(38) and Liu et al. (37), the bone resorption experiments had a
duration of 6–7 days. This long exposure on the TLR agonists
shows an effect on the expression of TNF-α. Accordingly, we
found a higher production of TNF-α on the conditions of TLR2
and TLR2+4 on day 3, in comparison with the control and
the TLR4 condition. This finding was reversed on day 7, where
TLR2 and TLR2+4 were significantly lower than the control. On
day 21, the only remaining difference we observed, was between
TLR2 and TLR4 conditions, with the former one being higher.
Apparently, the co-culture cell system normalizes over time: at
3 days all cultures containing TLR2 agonists responded with
increased TNF-α secretion, followed by the reverse on day 7 and
no differences between the conditions at day 21.
In this study, we investigated the chronic effect of the
TLR2 and TLR4 agonists on osteoclastogenesis and osteogenesis,
measuring several parameters. When observing an effect, it was
often TLR2 agonist-mediated. The ability of naive osteoclast
precursor cells to form osteoclasts, for instance, was consistently
inhibited by TLR2 agonists. Bone resorption also appeared to
be reduced by the addition of TLR2 agonists when added at
a late time point (day 14). TLR2 had also an evident effect
on the production of TNF-α, playing an enchasing role on
day 3, which was reversed at the later time points (days 14
and 21). At gene expression level, expression of NFATc1, a
key transcription regulator of osteoclast differentiation (50), was
downregulated on day 7 by TLR2 agonist. The only effect of
TLR4 on osteoclastogenesis was a slight reduction of the bone
resorption when it was added at a late time point (day 14).
Furthermore, it affected ALP gene expression, with an enhanced
expression at day 7. The combination of TLR2+4 agonists only
enhanced TNF-α gene expression during osteogenesis, both at
days 7 and 14.
In our previous study (24), we demonstrated that GF and
monocytes can mediate the diversity of the cellular populations
at the site of inflammation, by reducing the number of B-
, T- and NK-cells. In this aforementioned study, we also
showed that TLR2 activation is an important player in T cell
proliferation in the presence of monocytes (20). In the current
study, we showed that activation with TLR agonists of naive or
M-CSF and RANKL primed human osteoclast precursors has
differential effects. This could indicate that fresh monocytes that
encounter bacterial products such as TLR2 or TLR4 agonists, may
differentiate into macrophages that eradiate these inflammation
activators (Figure 7). Osteoclasts could be the cells that are NOT
activated by TLR directly, but rather indirectly, through the
microenvironment’s expression of inflammatory cytokines that
are known activators of osteoclasts.
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